Christopher Herbert
4 Papers
Christopher Herbert is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Michele Maio,Karl D. Lewis,Lev V. Demidov,Mario Mandalà,Igor Bondarenko,Paolo A. Ascierto,Christopher Herbert,Andrzej Mackiewicz,Piotr Rutkowski,Alexander Guminski,Grant R. Goodman,B. Simmons,Chenglin Ye,Yibing Yan,Dirk Schadendorf,Gabriela Cinat,Luis Fein,Michael C. Brown,Andrew Haydon,Adnan Khattak,Catriona M. McNeil,Phillip Parente,Jeremy Power,Rachel Roberts-Thomson,Shahneen Sandhu,Craig Underhill,Suresh Varma,Thomas Berger,Ahmad Awada,Nathalie Blockx,Veronique Buyse,Jeroen Mebis,Fabio Franke,Sergio J Azevedo,Nicolas Silva Lazaretti,Rahima Jamal,Catalin Mihalcioiu,Teresa M. Petrella,Kerry J. Savage,Xinni Song,Ralph Wong,Nina Dabelic,Stjepko Plestina,Zeljko Vojnovic,Petr Arenberger,Ivo Kocak,Ivana Krajsová,Eugen Kubala,Bohuslav Melichar,Yvetta Vantuchova,Kadri Putnik,Brigitte Dréno,Caroline Dutriaux,Jean-Jacques Grob,Pascal Joly,Jean-Philippe Lacour,Nicolas Meyer,Laurent Mortier,Luc Thomas,Michael Fluck,Thilo Gambichler,Jessica C. Hassel,Axel Hauschild,Paul Donnellan,John McCaffrey,Derek G. Power,Samuel Ariad,Gil Bar-Sela,Daniel Hendler,Ilan G. Ron,Jacob Schachter,Paolo A. Ascierto,Alfredo Berruti,Luca Bianchi,Vanna Chiarion Sileni,Francesco Cognetti,Riccardo Danielli,Anna Maria Di Giacomo,Luca Gianni,Aron Goldhirsch,Michele Guida,Paolo Marchetti,Paola Queirolo,Armando Santoro,Ellen Kapiteijn,Paula Ferreira,Georgy Gafton,Yulia Makarova,Zoran Andric,Nada Babovic,Darjana Jovanovic,Lidija Sekulovic,Graham Lawrence Cohen,Lydia Dreosti,Daniel A. Vorobiof,Maria Teresa Curiel Garcia,Roberto Diaz Beveridge,Margarita Majem Tarruella,Ivan Marquez Rodas,Jose-M Puliats Rodriguez,Antonio Rueda Dominguez,Marianne Maroti,Karin Papworth,Olivier Michielin,Ewan Brown,Pippa Corrie,Mark Harries,Satish Kumar,Agustin Martin-Clavijo,Mark R. Middleton,Poulam M. Patel,Toby Talbot,Sanjiv S. Agarwala,Paul B. Chapman,Robert M. Conry,Gary Doolittle,Tara C. Gangadhar,Sigrun Hallmeyer,Omid Hamid,Leonel Hernandez-Aya,Douglas B. Johnson,Frederic Kass,Tatjana Kolevska,Scott Lunin,April K.S. Salama,Branimir I. Sikic,Bradley Somer,David R. Spigel,Eric D. Whitman +128 more
TL;DR: The BRIM8 study evaluated adjuvant vemurafenib monotherapy in patients with resected, BRAFV600 mutation-positive melanoma and the result was not significant because of the prespecified hierarchical prerequisite for the primary disease-free survival analysis of cohort 2 to show a significant health benefit.
190
Pre-diagnostic blood biomarkers for adult glioma
TL;DR: In this article , the authors examined the evidence in the literature for pre-diagnostic biomarkers in glioma, including metabolomics and proteomics, and also considered the limitations of these approaches and future research directions of prediagnosis biomarkers.
7
Delphi panel for consensus on the optimal management of dabrafenib plus trametinib-related pyrexia in patients with melanoma
Ricky Frazer,Avinash Gupta,Christopher Herbert,Miranda Payne,S. Diaz-Mendoza,Sally-Anne Vincent,E.R. Kovaleva +6 more
TL;DR: A modified Delphi panel was conducted to develop consensus on the optimal management of dabrafenib and trametinib combination therapy (dab + tram)-related pyrexia in patients with melanoma as mentioned in this paper .
2
Dual Immunotherapy in a Patient with Rapidly Progressive Metastatic Melanoma Without Failure of Grafted Kidney
TL;DR: A 58-year-old female presented with a right axillary mass, which was confirmed as Stage IB BRAF-mutant melanoma based on the histology of the resected mass, and the patient fully consented regarding risks of graft loss.